Ion channels in innate and adaptive immunity

Annual Review of Immunology

Volumn 33, Issue , 2015, Pages 291-353

  Feske, Stefan ^a   Wulff, Heike ^b   Skolnik, Edward Y ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

B cells; Calcium; Chloride; CRAC; DC; Disease; Ion channels; KCa3.1; KV1.3; Macrophages; Magnesium; Mast cells; ORAI; Potassium; Sodium; STIM; T cells; Therapy; Transporters; TRP; Zinc

Indexed keywords

CALCIUM; CALCIUM CHANNEL; CALCIUM RELEASE ACTIVATED CALCIUM CHANNEL; CARRIER PROTEINS AND BINDING PROTEINS; CATION CHANNEL; CHLORIDE CHANNEL; HYDROGEN VOLTAGE GATED CHANNEL; INFLAMMASOME; ION CHANNEL; MAGNESIUM; MAGNESIUM CHANNEL; MAGNESIUM TRANSPORTER; MEMBRANE PROTEIN; PANNEXIN HEMICHANNEL; POTASSIUM CHANNEL; POTASSIUM CHANNEL KCA3.1; POTASSIUM CHANNEL KV1.3; PURINERGIC P2X RECEPTOR; PURINERGIC P2X7 RECEPTOR; SODIUM CHANNEL; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TRANSIENT RECEPTOR POTENTIAL CHANNEL M4; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL; ZINC; ZINC TRANSPORTER; CATION TRANSPORT PROTEIN;

ADAPTIVE IMMUNITY; AUTOIMMUNITY; CALCIUM SIGNALING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL SPECIFICITY; CELLULAR IMMUNITY; DENDRITIC CELL; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INNATE IMMUNITY; LYMPHOCYTE; LYMPHOCYTE FUNCTION; MACROPHAGE; MEMBRANE PERMEABILITY; MEMBRANE POTENTIAL; MONOCYTE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; ANIMAL; CYTOLOGY; GENETICS; HYPERSENSITIVITY; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGY; IMMUNOTHERAPY; MAST CELL; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; PHYSIOLOGY; PROCEDURES; SIGNAL TRANSDUCTION;

ADAPTIVE IMMUNITY; ANIMALS; CALCIUM CHANNELS; CATION TRANSPORT PROTEINS; HUMANS; HYPERSENSITIVITY; IMMUNITY, INNATE; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOTHERAPY; ION CHANNELS; LYMPHOCYTES; MAST CELLS; MOLECULAR TARGETED THERAPY; MUTATION; SIGNAL TRANSDUCTION;

EID: 84927596647     PISSN: 07320582     EISSN: 15453278     Source Type: Book Series    
DOI: 10.1146/annurev-immunol-032414-112212     Document Type: Review

References (385)

1. Cahalan MD, Chandy KG. 2009. The functional network of ion channels in T lymphocytes. Immunol. Rev. 231:59-87
2. Clapham DE. 2007. Calcium signaling. Cell 131:1047-58
3. Feske S. 2007. Calcium signalling in lymphocyte activation and disease. Nat. Rev. Immunol. 7:690-702
4. Feske S. 2009. ORAI1 and STIM1 deficiency in human and mice: roles of store-operated Ca2+ entry in the immune system and beyond. Immunol. Rev. 231:189-209
5. Oh-horaM. 2009. Calcium signaling in the development and function of T-lineage cells. Immunol. Rev. 231:210-24
6. Vig M, Kinet JP. 2009. Calcium signaling in immune cells. Nat. Immunol. 10:21-27
7. Launay P, Cheng H, Srivatsan S, Penner R, Fleig A, Kinet JP. 2004. TRPM4 regulates calcium oscillations after T cell activation. Science 306:1374-77
8. Launay P, FleigA, Perraud AL, Scharenberg AM, PennerR,Kinet JP. 2002.TRPM4is a Ca2+-activated nonselective cation channel mediating cell membrane depolarization. Cell 109:397-407
9. DeCoursey TE, Chandy KG, Gupta S, Cahalan MD. 1985. Voltage-dependent ion channels in T-lymphocytes. J. Neuroimmunol. 10:71-95
10. Matteson DR, Deutsch C. 1984. K channels in T lymphocytes: a patch clamp study using monoclonal antibody adhesion. Nature 307:468-71
11. Grissmer S,Dethlefs B,Wasmuth JJ, Goldin AL,Gutman GA, et al. 1990. Expression and chromosomal localization of a lymphocyte K+ channel gene. PNAS 87:9411-15
12. Joiner WJ, Wang LY, Tang MD, Kaczmarek LK. 1997. hSK4, a member of a novel subfamily of calcium-activated potassium channels. PNAS 94:11013-18
13. Fanger CM,Ghanshani S, Logsdon NJ, Rauer H, Kalman K, et al. 1999. Calmodulin mediates calciumdependent activation of the intermediate conductance KCa channel, IKCa1. J. Biol. Chem. 274:5746-54
14. Nicolaou SA, Neumeier L, Peng Y, Devor DC, Conforti L. 2007. The Ca2+-activated K+ channel KCa3.1 compartmentalizes in the immunological synapse of human T lymphocytes.Am. J. Physiol. Cell Physiol. 292:C1431-39
15. Cai X, Srivastava S, Sun Y, Li Z, Wu H, et al. 2011. Tripartite motif containing protein 27 negatively regulates CD4 T cells by ubiquitinating and inhibiting the class II PI3K-C2β. PNAS 108:20072-77
16. Srivastava S, Di L, Zhdanova O, Li Z, Vardhana S, et al. 2009. The class II phosphatidylinositol 3 kinase C2β is required for the activation of the K+ channel KCa3.1 and CD4 T-cells. Mol. Biol. Cell 20:3783-91
17. Gerlach AC, Syme CA, Giltinan L, Adelman JP, Devor DC. 2001. ATP-dependent activation of the intermediate conductance, Ca2+-activated K+ channel, hIK1, is conferred by a C-terminal domain. J. Biol. Chem. 276:10963-70
18. Srivastava S, Li Z, Ko K, Choudhury P, Albaqumi M, et al. 2006. Histidine phosphorylation of the potassium channel KCa3.1 by nucleoside diphosphate kinase B is required for activation of KCa3.1 and CD4 T cells. Mol. Cell 24:665-75
19. Srivastava S, Choudhury P, Li Z, Liu G, Nadkarni V, et al. 2006. Phosphatidylinositol 3-phosphate indirectly activates KCa3.1 via 14 amino acids in the carboxy terminus of KCa3.1. Mol. Biol. Cell 17:146-54
20. Srivastava S, Ko K, Choudhury P, Li Z, Johnson AK, et al. 2006. Phosphatidylinositol-3 phosphatase myotubularin-related protein 6 negatively regulates CD4 T cells. Mol. Cell. Biol. 26:5595-602
21. Srivastava S, Zhdanova O, Di L, Li Z, Albaqumi M, et al. 2008. Protein histidine phosphatase 1 negatively regulates CD4 T cells by inhibiting the K+ channel KCa3.1. PNAS 105:14442-46
22. Hoth M, Penner R. 1992. Depletion of intracellular calcium stores activates a calcium current in mast cells. Nature 355:353-56
23. Lewis RS, Cahalan MD. 1989. Mitogen-induced oscillations of cytosolic Ca2+ and transmembrane Ca2+ current in human leukemic T cells. Cell. Regul. 1:99-112
24. Zweifach A, LewisRS. 1993. Mitogen-regulated Ca2+ current ofTlymphocytes is activated by depletion of intracellular Ca2+ stores. PNAS 90:6295-99
25. Ernst IM, Fliegert R, Guse AH. 2013. Adenine dinucleotide second messengers and T-lymphocyte calcium signaling. Front. Immunol. 4:259
26. Feske S, Gwack Y, Prakriya M, Srikanth S, Puppel SH, et al. 2006. A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function. Nature 441:179-85
27. Liou J, Kim M, Heo WD, Jones JT, Myers JW, et al. 2005. STIM is a Ca2+ sensor essential for Ca2+-store-depletion-triggered Ca2+ influx. Curr. Biol. 15:1235-41
28. Roos J, DiGregorio PJ, Yeromin AV, Ohlsen K, Lioudyno M, et al. 2005. STIM1, an essential and conserved component of store-operated Ca2+ channel function. J. Cell Biol. 169:435-45
29. Vig M, Peinelt C, Beck A, Koomoa DL, Rabah D, et al. 2006. CRACM1 is a plasma membrane protein essential for store-operated Ca2+ entry. Science 312:1220-23
30. Zhang SL, Yeromin AV, Zhang XH, Yu Y, Safrina O, et al. 2006. Genome-wide RNAi screen of Ca2+ influx identifies genes that regulate Ca2+ release-activated Ca2+ channel activity. PNAS 103:9357-62
31. Feske S. 2010. CRAC channelopathies. Pflugers Arch. 460:417-35
32. Gwack Y, Srikanth S, Feske S, Cruz-Guilloty F, Oh-hora M, et al. 2007. Biochemical and functional characterization of Orai proteins. J. Biol. Chem. 282:16232-43
33. McCarl CA, Picard C, Khalil S, Kawasaki T, Rother J, et al. 2009. ORAI1 deficiency and lack of storeoperated Ca2+ entry cause immunodeficiency, myopathy, and ectodermal dysplasia. J. Allergy Clin. Immunol. 124:1311-18.e7
34. Williams RT, Manji SS, Parker NJ, Hancock MS, Van Stekelenburg L, et al. 2001. Identification and characterization of the STIM (stromal interaction molecule) gene family: coding for a novel class of transmembrane proteins. Biochem. J. 357:673-85
35. Prakriya M, Feske S, Gwack Y, Srikanth S, Rao A, Hogan PG. 2006. Orai1 is an essential pore subunit of the CRAC channel. Nature 443:230-33
36. Vig M, Beck A, Billingsley JM, Lis A, Parvez S, et al. 2006. CRACM1 multimers form the ion-selective pore of the CRAC channel. Curr. Biol. 16:2073-79
37. Yeromin AV, Zhang SL, JiangW, Yu Y, Safrina O, Cahalan MD. 2006. Molecular identification of the CRAC channel by altered ion selectivity in a mutant of Orai. Nature 443:226-29
38. McNally BA, Yamashita M, Engh A, Prakriya M. 2009. Structural determinants of ion permeation in CRAC channels. PNAS 106:22516-21
39. Zhou Y, Ramachandran S, Oh-hora M, Rao A, Hogan PG. 2010. Pore architecture of the ORAI1 store-operated calcium channel. PNAS 107:4896-901
40. LisA, Peinelt C, Beck A, Parvez S, Monteilh-ZollerM, et al. 2007.CRACM1,CRACM2, andCRACM3 are store-operated Ca2+ channels with distinct functional properties. Curr. Biol. 17:794-800
41. Stathopulos PB, Zheng L, Li GY, Plevin MJ, Ikura M. 2008. Structural and mechanistic insights into STIM1-mediated initiation of store-operated calcium entry. Cell 135:110-22
42. Hogan PG, Lewis RS, Rao A. 2010. Molecular basis of calcium signaling in lymphocytes: STIM and ORAI. Annu. Rev. Immunol. 28:491-533
43. Lewis RS. 2011. Store-operated calcium channels: new perspectives on mechanism and function. Cold Spring Harb. Perspect. Biol. 3:a003970
44. Shaw PJ, Qu B, Hoth M, Feske S. 2013. Molecular regulation of CRAC channels and their role in lymphocyte function. Cell. Mol. Life Sci. 70:2637-56
45. Shaw PJ, Feske S. 2012. Regulation of lymphocyte function by ORAI and STIM proteins in infection and autoimmunity. J. Physiol. 590:4157-67
46. Di L, Srivastava S, Zhdanova O, Sun Y,LiZ, Skolnik EY. 2010. Nucleoside diphosphate kinase B knockout mice have impaired activation of the K+ channel KCa3.1, resulting in defective T cell activation. J. Biol. Chem. 285:38765-71
47. Hess SD, Oortgiesen M, Cahalan MD. 1993. Calcium oscillations in human T and natural killer cells depend upon membrane potential and calcium influx. J. Immunol. 150:2620-33
48. Leonard RJ, Garcia ML, Slaughter RS, Reuben JP. 1992. Selective blockers of voltage-gated K+ channels depolarize human T lymphocytes: mechanism of the antiproliferative effect of charybdotoxin. PNAS 89:10094-98
49. Wu LJ, Sweet TB, Clapham DE. 2010. International Union of Basic and Clinical Pharmacology. LXXVI. Current progress in the mammalian TRP ion channel family. Pharmacol. Rev. 62:381-404
50. Billeter AT, Hellmann JL, Bhatnagar A, Polk HC Jr. 2014. Transient receptor potential ion channels: powerful regulators of cell function. Ann. Surg. 259:229-35
51. Moran MM, McAlexander MA, Biro T, Szallasi A. 2011. Transient receptor potential channels as therapeutic targets. Nat. Rev. Drug Discov. 10:601-20
52. Perraud AL, Fleig A, Dunn CA, Bagley LA, Launay P, et al. 2001. ADP-ribose gating of the calciumpermeable LTRPC2 channel revealed by Nudix motif homology. Nature 411:595-99
53. Sano Y, Inamura K, Miyake A, Mochizuki S, Yokoi H, et al. 2001. Immunocyte Ca2+ influx system mediated by LTRPC2. Science 293:1327-30
54. Beck A, Kolisek M, Bagley LA, Fleig A, Penner R. 2006. Nicotinic acid adenine dinucleotide phosphate and cyclic ADP-ribose regulate TRPM2 channels in T lymphocytes. FASEB J. 20:962-64
55. Perraud AL, Schmitz C, Scharenberg AM. 2003. TRPM2 Ca2+ permeable cation channels: from gene to biological function. Cell Calcium 33:519-31
56. SaitoM,Hanson PI, Schlesinger P. 2007. Luminal chloride-dependent activation of endosome calcium channels: patch clamp study of enlarged endosomes. J. Biol. Chem. 282:27327-33
57. Nagasawa M, Nakagawa Y, Tanaka S, Kojima I. 2007. Chemotactic peptide fMetLeuPhe induces translocation of the TRPV2 channel in macrophages. J. Cell. Physiol. 210:692-702
58. Link TM, Park U, Vonakis BM, Raben DM, Soloski MJ, CaterinaMJ. 2010. TRPV2 has a pivotal role in macrophage particle binding and phagocytosis. Nat. Immunol. 11:232-39
59. Idzko M, Ferrari D, Eltzschig HK. 2014. Nucleotide signalling during inflammation. Nature 509:310-17
60. Le Feuvre RA, Brough D, Iwakura Y, Takeda K, Rothwell NJ. 2002. Priming of macrophages with lipopolysaccharide potentiates P2X7-mediated cell death via a caspase-1-dependent mechanism, independently of cytokine production. J. Biol. Chem. 277:3210-18
61. Mehta N, Kaur M, Singh M, Chand S, Vyas B, et al. 2014. Purinergic receptor P2X(7): a novel target for anti-inflammatory therapy. Bioorg. Med. Chem. 22:54-88
62. Ferrari D, Pizzirani C, Adinolfi E, Lemoli RM, Curti A, et al. 2006. The P2X7 receptor: a key player in IL-1 processing and release. J. Immunol. 176:3877-83
63. Junger WG. 2011. Immune cell regulation by autocrine purinergic signalling. Nat. Rev. Immunol. 11:201-12
64. Trautmann A. 2009. Extracellular ATP in the immune system: more than just a "danger signal." Sci. Signal. 2:pe6
65. Adamson SE, LeitingerN. 2014. The role of pannexin1 in the induction and resolution of inflammation. FEBS Lett. 588:1416-22
66. Chekeni FB, Elliott MR, Sandilos JK, Walk SF, Kinchen JM, et al. 2010. Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis. Nature 467:863-67
67. Catterall WA. 2011. Voltage-gated calcium channels. Cold Spring Harb. Perspect. Biol. 3:a003947
68. Omilusik K, Priatel JJ, Chen X, Wang YT, Xu H, et al. 2011. The CaV1.4 calcium channel is a critical regulator of T cell receptor signaling and naive T cell homeostasis. Immunity 5(3):349-60
69. Badou A, Jha MK, Matza D, Mehal WZ, Freichel M, et al. 2006. Critical role for the beta regulatory subunits of Cav channels in T lymphocyte function. PNAS 103:15529-34
70. Jha MK, Badou A, Meissner M, McRory JE, Freichel M, et al. 2009. Defective survival of naive CD8+ T lymphocytes in the absence of the β3 regulatory subunit of voltage-gated calcium channels. Nat. Immunol. 10:1275-82
71. Cabral MD, Paulet PE, Robert V, Gomes B, Renoud ML, et al. 2010. Knocking down Cav1 calcium channels implicated in Th2 cell activation prevents experimental asthma. Am. J. Respir. Crit. CareMed. 181:1310-17
72. Di L, Srivastava S, Zhdanova O, Ding Y, Li Z, et al. 2010. Inhibition of the K+ channel KCa3.1 ameliorates T cell-mediated colitis. PNAS 107:1541-46
73. Brandao K, Deason-Towne F, Perraud AL, Schmitz C. 2013. The role of Mg2+ in immune cells. Immunol. Res. 55:261-69
74. Scarpa A, Brinley FJ. 1981. In situ measurements of free cytosolic magnesium ions. Fed. Proc. 40:2646-52
75. Li FY, Chaigne-Delalande B, Kanellopoulou C, Davis JC, MatthewsHF, et al. 2011. Second messenger role for Mg2+ revealed by human T-cell immunodeficiency. Nature 475:471-76
76. Goytain A, Quamme GA. 2005. Identification and characterization of a novel mammalian Mg2+ transporter with channel-like properties. BMC Genomics 6:48
77. Zhou H, Clapham DE. 2009. Mammalian MagT1 and TUSC3 are required for cellular magnesium uptake and vertebrate embryonic development. PNAS 106:15750-55
78. Bates-Withers C, Sah R, Clapham DE. 2011. TRPM7, the Mg2+ inhibited channel and kinase. Adv. Exp. Med. Biol. 704:173-83
79. Bae CY, Sun HS. 2011. TRPM7 in cerebral ischemia and potential target for drug development in stroke. Acta Pharmacol. Sin. 32:725-33
80. Aydemir TB, Liuzzi JP, McClellan S, Cousins RJ. 2009. Zinc transporter ZIP8 (SLC39A8) and zinc influence IFN-γexpression in activated human T cells. J. Leukoc. Biol. 86:337-48
81. Kaltenberg J, Plum LM,Ober-Blobaum JL,Honscheid A, Rink L, HaaseH. 2010. Zinc signals promote IL-2-dependent proliferation of T cells. Eur. J. Immunol. 40:1496-503
82. Yu M, Lee WW, Tomar D, Pryshchep S, Czesnikiewicz-Guzik M, et al. 2011. Regulation of T cell receptor signaling by activation-induced zinc influx. J. Exp. Med. 208:775-85
83. Haase H, Hebel S, Engelhardt G, Rink L. 2006. Flow cytometric measurement of labile zinc in peripheral blood mononuclear cells. Anal. Biochem. 352:222-30
84. Rukgauer M, Klein J,Kruse-Jarres JD. 1997. Reference values for the trace elements copper, manganese, selenium, and zinc in the serum/plasma of children, adolescents, and adults. J. Trace Elem. Med. Biol. 11:92-98
85. Huang L, Tepaamorndech S. 2013. The SLC30 family of zinc transporters- A review of current understanding of their biological and pathophysiological roles. Mol. Aspects Med. 34:548-60
86. Jeong J, Eide DJ. 2013. The SLC39 family of zinc transporters. Mol. Aspects Med. 34:612-19
87. Lichten LA, Cousins RJ. 2009. Mammalian zinc transporters: nutritional and physiologic regulation. Annu. Rev. Nutr. 29:153-76
88. Dufner-Beattie J, Huang ZL, Geiser J, Xu W, Andrews GK. 2005. Generation and characterization of mice lacking the zinc uptake transporter ZIP3. Mol. Cell. Biol. 25:5607-15
89. Overbeck S, Uciechowski P, Ackland ML, Ford D, Rink L. 2008. Intracellular zinc homeostasis in leukocyte subsets is regulated by different expression of zinc exporters ZnT-1 to ZnT-9. J. Leukoc. Biol. 83:368-80
90. Nishida K, Hasegawa A, Nakae S, Oboki K, Saito H, et al. 2009. Zinc transporter Znt5/Slc30a5 is required for the mast cell-mediated delayed-type allergic reaction but not the immediate-type reaction. J. Exp. Med. 206:1351-64
91. Cahalan MD, Chandy KG, DeCoursey TE, Gupta S. 1985. A voltage-gated potassium channel in human T lymphocytes. J. Physiol. 358:197-237
92. Verheugen JA, Oortgiesen M, Vijverberg HP. 1994. Veratridine blocks voltage-gated potassium current in human T lymphocytes and in mouse neuroblastoma cells. J. Membr. Biol. 137:205-14
93. Fraser SP, Diss JK, Lloyd LJ, Pani F, Chioni AM, et al. 2004. T-lymphocyte invasiveness: control by voltage-gated Na+ channel activity. FEBS Lett. 569:191-94
94. Lai ZF, Chen YZ, Nishimura Y, Nishi K. 2000. An amiloride-sensitive and voltage-dependent Na+ channel in an HLA-DR-restricted human T cell clone. J. Immunol. 165:83-90
95. Lo WL, Donermeyer DL, Allen PM. 2012. A voltage-gated sodium channel is essential for the positive selection of CD4+ T cells. Nat. Immunol. 13:880-87
96. Carrithers MD, Dib-Hajj S, Carrithers LM, Tokmoulina G, Pypaert M, et al. 2007. Expression of the voltage-gated sodium channel NaV1.5 in the macrophage late endosome regulates endosomal acidification. J. Immunol. 178:7822-32
97. Carrithers LM, Hulseberg P, Sandor M, CarrithersMD. 2011. The human macrophage sodium channel NaV1.5 regulates mycobacteria processing through organelle polarization and localized calcium oscillations. FEMS Immunol. Med. Microbiol. 63:319-27
98. Black JA, Newcombe J, Waxman SG. 2013. Nav1.5 sodium channels in macrophages in multiple sclerosis lesions. Mult. Scler. 19:532-42
99. Craner MJ, Damarjian TG, Liu S, Hains BC, Lo AC, et al. 2005. Sodium channels contribute to microglia/macrophage activation and function in EAE and MS. Glia 49:220-29
100. Zsiros E, Kis-Toth K, Hajdu P, Gaspar R, Bielanska J, et al. 2009. Developmental switch of the expression of ion channels in human dendritic cells. J. Immunol. 183:4483-92
101. Voss FK, Ullrich F, Munch J, Lazarow K, Lutter D, et al. 2014. Identification of LRRC8 heteromers as an essential component of the volume-regulated anion channel VRAC. Science 344:634-38
102. Qiu Z, Dubin AE, Mathur J, Tu B, Reddy K, et al. 2014. SWELL1, a plasma membrane protein, is an essential component of volume-regulated anion channel. Cell 157:447-58
103. Tian J, Lu Y, Zhang H, Chau CH, Dang HN, Kaufman DL. 2004. Gamma-aminobutyric acid inhibits T cell autoimmunity and the development of inflammatory responses in a mouse type 1 diabetes model. J. Immunol. 173:5298-304
104. Mendu SK, Akesson L, Jin Z, Edlund A, Cilio C, et al. 2011. Increased GABAA channel subunits expression in CD8+ but not in CD4+ T cells in BB rats developing diabetes compared to their congenic littermates. Mol. Immunol. 48:399-407
105. Moss RB, Bocian RC, Hsu YP, Dong YJ, Kemna M, et al. 1996. Reduced IL-10 secretion by CD4+ T lymphocytes expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR). Clin. Exp. Immunol. 106:374-88
106. Chen JH, Schulman H, Gardner P. 1989. A cAMP-regulated chloride channel in lymphocytes that is affected in cystic fibrosis. Science 243:657-60
107. Decoursey TE. 2012. Voltage-gated proton channels. Compr. Physiol. 2:1355-85
108. Demaurex N, El Chemaly A. 2010. Physiological roles of voltage-gated proton channels in leukocytes. J. Physiol. 588:4659-65
109. DeCoursey TE. 2013. Voltage-gated proton channels: molecular biology, physiology, and pathophysiology of the HV family. Physiol. Rev. 93:599-652
110. El Chemaly A, Okochi Y, Sasaki M, Arnaudeau S, Okamura Y, Demaurex N. 2010. VSOP/Hv1 proton channels sustain calcium entry, neutrophil migration, and superoxide production by limiting cell depolarization and acidification. J. Exp. Med. 207:129-39
111. Morgan D, Capasso M, Musset B, Cherny VV, Rios E, et al. 2009. Voltage-gated proton channels maintain pH in human neutrophils during phagocytosis. PNAS 106:18022-27
112. Capasso M, Bhamrah MK, Henley T, Boyd RS, Langlais C, et al. 2010. HVCN1 modulates BCR signal strength via regulation of BCR-dependent generation of reactive oxygen species. Nat. Immunol. 11:265-72
113. Roos A, BoronWF. 1981. Intracellular pH. Physiol. Rev. 61:296-434
114. Meuth SG, Bittner S, Meuth P, Simon OJ, Budde T, Wiendl H. 2008. TWIK-related acid-sensitive K+ channel 1 (TASK1) and TASK3 critically influence T lymphocyte effector functions. J. Biol. Chem. 283:14559-70
115. Bittner S, BobakN,Herrmann AM, Gobel K,Meuth P, et al. 2010. Upregulation of K2P5.1 potassium channels in multiple sclerosis. Ann. Neurol. 68:58-69
116. Bobak N, Bittner S, Andronic J, Hartmann S, Muhlpfordt F, et al. 2011. Volume regulation of murine T lymphocytes relies on voltage-dependent and two-pore domain potassium channels. Biochim. Biophys. Acta 1808:2036-44
117. Bittner S, Meuth SG, Gobel K,MelzerN,Herrmann AM, et al. 2009. TASK1modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system. Brain 132:2501-16
118. Aifantis I, Gounari F, Scorrano L, Borowski C, Von Boehmer H. 2001. Constitutive pre-TCR signaling promotes differentiation through Ca2+ mobilization and activation ofNF-κBandNFAT. Nat. Immunol. 2:403-9
119. Bhakta NR, Oh DY, Lewis RS. 2005. Calcium oscillations regulate thymocyte motility during positive selection in the three-dimensional thymic environment. Nat. Immunol. 6:143-51
120. Daniels MA, Teixeiro E, Gill J, Hausmann B, Roubaty D, et al. 2006. Thymic selection threshold defined by compartmentalization of Ras/MAPK signalling. Nature 444:724-29
121. Nakayama T, Ueda Y, Yamada H, Shores EW, Singer A, June CH. 1992. In vivo calcium elevations in thymocytes with T cell receptors that are specific for self ligands. Science 257:96-99
122. Feske S, Muller JM, Graf D, Kroczek RA, Drager R, et al. 1996. Severe combined immunodeficiency due to defective binding of the nuclear factor of activated T cells in T lymphocytes of two male siblings. Eur. J. Immunol. 26:2119-26
123. Fuchs S, Rensing-Ehl A, Speckmann C, Bengsch B, Schmitt-Graeff A, et al. 2012. Antiviral and regulatory T cell immunity in a patient with stromal interaction molecule 1 deficiency. J. Immunol. 188:1523-33
124. Le Deist F,Hivroz C, Partiseti M, Thomas C, BucHA, et al. 1995. A primary T-cell immunodeficiency associated with defective transmembrane calcium influx. Blood 85:1053-62
125. Picard C, McCarl CA, Papolos A, Khalil S, Luthy K, et al. 2009. STIM1 mutation associated with a syndrome of immunodeficiency and autoimmunity. N. Engl. J. Med. 360:1971-80
126. Gwack Y, Srikanth S, Oh-hora M, Hogan PG, Lamperti ED, et al. 2008. Hair loss and defective T-and B-cell function in mice lacking ORAI1. Mol. Cell. Biol. 28:5209-22
127. McCarl CA, Khalil S, Ma J, Oh-horaM, Yamashita M, et al. 2010. Store-operated Ca2+ entry through ORAI1 is critical for T cell-mediated autoimmunity and allograft rejection. J. Immunol. 185:5845-58
128. Beyersdorf N, Braun A, Vogtle T, Varga-Szabo D, Galdos R, et al. 2009. STIM1-independent T cell development and effector function in vivo. J. Immunol. 182:3390-97
129. Vig M, DeHaven WI, Bird GS, Billingsley JM, Wang H, et al. 2008. Defective mast cell effector functions inmice lacking theCRACM1pore subunit of store-operated calcium release-activated calcium channels. Nat. Immunol. 9:89-96
130. Baba Y, Nishida K, Fujii Y, Hirano T, Hikida M, Kurosaki T. 2008. Essential function for the calcium sensor STIM1 in mast cell activation and anaphylactic responses. Nat. Immunol. 9:81-88
131. Oh-hora M, Yamashita M, Hogan PG, Sharma S, Lamperti E, et al. 2008. Dual functions for the endoplasmic reticulum calcium sensors STIM1 and STIM2 in T cell activation and tolerance. Nat. Immunol. 9:432-43
132. Oh-horaM,Komatsu N, PishyarehM, Feske S, Hori S, et al. 2013. Agonist-selectedTcell development requires strong T cell receptor signaling and store-operated calcium entry. Immunity 38:881-95
133. Grgic I, Wulff H, Eichler I, Flothmann C, Kohler R, Hoyer J. 2009. Blockade of T-lymphocyte KCa3.1 and Kv1.3 channels as novel immunosuppression strategy to prevent kidney allograft rejection. Transplant. Proc. 41:2601-6
134. Gocke AR, Lebson LA, Grishkan IV, Hu L, Nguyen HM, et al. 2012. Kv1.3 deletion biases T cells toward an immunoregulatory phenotype and renders mice resistant to autoimmune encephalomyelitis. J. Immunol. 188:5877-86
135. Ouyang K, Leandro Gomez-Amaro R, Stachura DL, Tang H, Peng X, et al. 2014. Loss of IP3Rdependent Ca2+ signalling in thymocytes leads to aberrant development and acute lymphoblastic leukemia. Nat. Commun. 5:4814
136. Stritesky GL, Jameson SC, Hogquist KA. 2012. Selection of self-reactive T cells in the thymus. Annu. Rev. Immunol. 30:95-114
137. Brigl M, Bry L, Kent SC, Gumperz JE, Brenner MB. 2003. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat. Immunol. 4:1230-37
138. Kronenberg M, Kinjo Y. 2009. Innate-like recognition of microbes by invariant natural killer T cells. Curr. Opin. Immunol. 21:391-96
139. Godfrey DI, Berzins SP. 2007. Control points in NKT-cell development. Nat. Rev. Immunol. 7:505-18
140. Lin J, Krishnaraj R, Kemp RG. 1985. Exogenous ATP enhances calcium influx in intact thymocytes. J. Immunol. 135:3403-10
141. Chused TM, Apasov S, Sitkovsky M. 1996. Murine T lymphocytes modulate activity of an ATPactivated P2Z-type purinoceptor during differentiation. J. Immunol. 157:1371-80
142. Ross PE, EhringGR, Cahalan MD. 1997. Dynamics of ATP-induced calcium signaling in singlemouse thymocytes. J. Cell Biol. 138:987-98
143. Pizzo P, Zanovello P, Bronte V, Di Virgilio F. 1991. Extracellular ATPcauses lysis of mouse thymocytes and activates a plasma membrane ion channel. Biochem. J. 274(Pt. 1):139-44
144. Freedman BD, Liu QH, Gaulton G, Kotlikoff MI, Hescheler J, Fleischmann BK. 1999. ATP-evoked Ca2+ transients and currents inmurine thymocytes: possible role for P2X receptors in death by neglect. Eur. J. Immunol. 29:1635-46
145. Mulryan K, Gitterman DP, Lewis CJ, Vial C, Leckie BJ, et al. 2000. Reduced vas deferens contraction and male infertility in mice lacking P2X1 receptors. Nature 403:86-89
146. Solle M, Labasi J, Perregaux DG, Stam E, Petrushova N, et al. 2001. Altered cytokine production in mice lacking P2X(7) receptors. J. Biol. Chem. 276:125-32
147. Yamamoto K, Sokabe T, MatsumotoT, Yoshimura K, Shibata M, et al. 2006. Impaired flow-dependent control of vascular tone and remodeling in P2X4-deficient mice. Nat. Med. 12:133-37
148. Cockayne DA, Dunn PM, Zhong Y, Rong W, Hamilton SG, et al. 2005. P2X2 knockout mice and P2X2/P2X3 double knockout mice reveal a role for the P2X2 receptor subunit in mediating multiple sensory effects of ATP. J. Physiol. 567:621-39
149. Li FY, Chaigne-Delalande B, Su H, Uzel G, Matthews H, Lenardo MJ. 2014. XMEN disease: a new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus. Blood 123:2148-52
150. Jin J, Desai BN,Navarro B, Donovan A, Andrews NC, Clapham DE. 2008. Deletion of Trpm7 disrupts embryonic development and thymopoiesis without altering Mg2+ homeostasis. Science 322:756-60
151. Ackland ML, Michalczyk A. 2006. Zinc deficiency and its inherited disorders- A review. Genes Nutr. 1:41-49
152. Fraker PJ, King LE. 2004. Reprogramming of the immune system during zinc deficiency. Annu. Rev. Nutr. 24:277-98
153. Kury S, Dreno B, Bezieau S, Giraudet S, Kharfi M, et al. 2002. Identification of SLC39A4, a gene involved in acrodermatitis enteropathica. Nat. Genet. 31:239-40
154. Wang K, Zhou B, Kuo YM, Zemansky J, Gitschier J. 2002. A novel member of a zinc transporter family is defective in acrodermatitis enteropathica. Am. J. Hum. Genet. 71:66-73
155. Geiser J, Venken KJ,De Lisle RC, Andrews GK. 2012. Amousemodel of acrodermatitis enteropathica: loss of intestine zinc transporterZIP4 (Slc39a4) disrupts the stem cell niche and intestine integrity. PLOS Genet. 8:e1002766
156. Kumar L, Chou J, Yee CS, Borzutzky A, Vollmann EH, et al. 2014. Leucine-rich repeat containing 8A (LRRC8A) is essential for T lymphocyte development and function. J. Exp. Med. 211:929-42
157. Szabò I, Lepple-Wienhues A, Kaba KN, Zoratti M, Gulbins E, Lang F. 1998. Tyrosine kinasedependent activation of a chloride channel in CD95-induced apoptosis in T lymphocytes. PNAS 95:6169-74
158. Feske S, Giltnane J, Dolmetsch R, Staudt LM, Rao A. 2001. Gene regulation mediated by calcium signals in T lymphocytes. Nat. Immunol. 2:316-24
159. MatsumotoM, Fujii Y, Baba A, Hikida M, Kurosaki T, Baba Y. 2011. The calcium sensors STIM1 and STIM2 control B cell regulatory function through interleukin-10 production. Immunity 34:703-14
160. Limnander A, Depeille P, Freedman TS, Liou J, Leitges M, et al. 2011. STIM1, PKC-δ and RasGRP set a threshold for proapoptotic Erk signaling during B cell development. Nat. Immunol. 12:425-33
161. Miller AT, Sandberg M, Huang YH, Young M, Sutton S, et al. 2007. Production of Ins(1,3,4,5)P4 mediated by the kinase Itpkb inhibits store-operated calcium channels and regulates B cell selection and activation. Nat. Immunol. 8:514-21
162. Miyai T, Hojyo S, Ikawa T, Kawamura M, Irie T, et al. 2014. Zinc transporter SLC39A10/ZIP10 facilitates antiapoptotic signaling during early B-cell development. PNAS 111:11780-85
163. Sawada A, Takihara Y, Kim JY, Matsuda-Hashii Y, Tokimasa S, et al. 2003. A congenital mutation of the novel gene LRRC8 causes agammaglobulinemia in humans. J. Clin. Investig. 112:1707-13
164. Byun M, Abhyankar A, Lelarge V, Plancoulaine S, Palanduz A, et al. 2010. Whole-exome sequencingbased discovery of STIM1 deficiency in a child with fatal classic Kaposi sarcoma. J. Exp.Med. 207:2307-12
165. Feske S. 2011. Immunodeficiency due to defects in store-operated calcium entry. Ann. NY Acad. Sci. 1238:74-90
166. Feske S, Prakriya M, Rao A, Lewis RS. 2005. A severe defect in CRAC Ca2+ channel activation and altered K+ channel gating in T cells from immunodeficient patients. J. Exp. Med. 202:651-62
167. Ma J, McCarl CA, Khalil S, Luthy K, Feske S. 2010. T-cell-specific deletion of STIM1 and STIM2 protects mice from EAE by impairing the effector functions of Th1 and Th17 cells. Eur. J. Immunol. 40:3028-42
168. Kim KD, Srikanth S, Yee MK, Mock DC, Lawson GW, Gwack Y. 2011. ORAI1 deficiency impairs activated T cell death and enhances T cell survival. J. Immunol. 187:3620-30
169. Macian F. 2005. NFAT proteins: key regulators ofT-cell development and function. Nat. Rev. Immunol. 5:472-84
170. Feske S, Draeger R, PeterHH, Eichmann K, Rao A. 2000. The duration of nuclear residence ofNFAT determines the pattern of cytokine expression in human SCID T cells. J. Immunol. 165:297-305
171. Kim KD, Srikanth S, Tan YV, YeeMK, JewM, et al. 2014. Calcium signaling via Orai1 is essential for induction of the nuclear orphan receptor pathway to drive Th17 differentiation. J. Immunol. 192:110-22
172. Schuhmann MK, Stegner D, Berna-Erro A, Bittner S, Braun A, et al. 2010. Stromal interaction molecules 1 and 2 are key regulators of autoreactive T cell activation in murine autoimmune central nervous system inflammation. J. Immunol. 184:1536-42
173. Weidinger C, Shaw PJ, Feske S. 2013. STIM1 and STIM2-mediated Ca2+ influx regulates antitumour immunity by CD8+ T cells. EMBO Mol. Med. 5:1311-21
174. Lee YK, Turner H, Maynard CL, Oliver JR, Chen D, et al. 2009. Late developmental plasticity in the T helper 17 lineage. Immunity 30:92-107
175. Zhou L, Chong MM, Littman DR. 2009. Plasticity of CD4+ T cell lineage differentiation. Immunity 30:646-55
176. Dearman RJ, Kimber I. 2000. Role of CD4+ T helper 2-type cells in cutaneous inflammatory responses induced by fluorescein isothiocyanate. Immunology 101:442-51
177. Yu Y, Wang D, Liu C, Kaosaard K, Semple K, et al. 2011. Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORγt in mice. Blood 118:5011-20
178. Maynard CL, Weaver CT. 2009. Intestinal effector T cells in health and disease. Immunity 31:389-400
179. Jin S, Chin J, Kitson C,Woods J, Majmudar R, et al. 2013. Natural regulatory T cells are resistant to calcium release-activated calcium (CRAC/ORAI) channel inhibition. Int. Immunol. 25:497-506
180. Curotto de Lafaille MA, Lafaille JJ. 2009. Natural and adaptive Foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 30:626-35
181. Greenberg ML, Yu Y, Leverrier S, Zhang SL, Parker I, Cahalan MD. 2013. Orai1 function is essential for T cell homing to lymph nodes. J. Immunol. 190:3197-206
182. Waite JC, Vardhana S, Shaw PJ, Jang JE, McCarl CA, et al. 2013. Interference with Ca2+ release activated Ca2+ (CRAC) channel function delays T-cell arrest in vivo. Eur. J. Immunol. 43:3343-54
183. Negulescu PA, Krasieva TB, Khan A, Kerschbaum HH, Cahalan MD. 1996. Polarity of T cell shape, motility, and sensitivity to antigen. Immunity 4:421-30
184. MacLennan IC, Gotch FM, Golstein P. 1980. Limited specific T-cell mediated cytolysis in the absence of extracellular Ca2+. Immunology 39:109-17
185. Takayama H, SitkovskyMV. 1987. Antigen receptor-regulated exocytosis in cytotoxic T lymphocytes. J. Exp. Med. 166:725-43
186. Shaw PJ, WeidingerC, Vaeth M, LuethyK,Kaech S, Feske S. 2014.CD4+ andCD8+ Tcell-dependent antiviral immunity requires STIM1 and STIM2. J. Clin. Investig. 124:4549-63
187. Maul-Pavicic A, Chiang SC, Rensing-Ehl A, Jessen B, Fauriat C, et al. 2011. ORAI1-mediated calcium influx is required for human cytotoxic lymphocyte degranulation and target cell lysis. PNAS 108:3324-29
188. Sahin G, Palanduz A, Aydogan G, Cassar O, Ertem AU, et al. 2010. Classic Kaposi sarcoma in 3 unrelated Turkish children born to consanguineous kindreds. Pediatrics 125:e704-8
189. Robert V, Triffaux E, Paulet PE,Guery JC, Pelletier L, Savignac M. 2014. Protein kinase C-dependent activation of CaV1.2 channels selectively controls human TH2-lymphocyte functions. J. Allergy Clin. Immunol. 133:1175-83
190. Splawski I,Timothy K, Sharpe L,DecherN,Kumar P, et al. 2004. CaV1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 119:19-31
191. Strom TM, Nyakatura G, Apfelstedt-Sylla E, Hellebrand H, Lorenz B, et al. 1998. An L-type calciumchannel genemutated in incomplete X-linked congenital stationary night blindness. Nat. Genet. 19:260-63
192. Striessnig J, Bolz HJ, Koschak A. 2010. Channelopathies in Cav1.1, Cav1.3, and Cav1.4 voltage-gated L-type Ca2+ channels. Pflugers Arch. 460:361-74
193. Baricordi OR, Ferrari D, Melchiorri L, Chiozzi P, Hanau S, et al. 1996. An ATP-activated channel is involved in mitogenic stimulation of human T lymphocytes. Blood 87:682-90
194. Padeh S, Cohen A, Roifman CM. 1991. ATP-induced activation of human B lymphocytes via P2-purinoceptors. J. Immunol. 146:1626-32
195. Adinolfi E, Callegari MG, Ferrari D, Bolognesi C, Minelli M, et al. 2005. Basal activation of the P2X7 ATP receptor elevatesmitochondrial calcium and potential, increases cellular ATP levels, and promotes serum-independent growth. Mol. Biol. Cell 16:3260-72
196. Woehrle T, Yip L, Elkhal A, Sumi Y, Chen Y, et al. 2010. Pannexin-1 hemichannel-mediated ATP release together with P2X1 and P2X4 receptors regulate T-cell activation at the immune synapse. Blood 116:3475-84
197. Schenk U, Westendorf AM, Radaelli E, Casati A, Ferro M, et al. 2008. Purinergic control of T cell activation by ATP released through pannexin-1 hemichannels. Sci. Signal. 1:ra6
198. Schenk U, Frascoli M, Proietti M, Geffers R, Traggiai E, et al. 2011. ATP inhibits the generation and function of regulatory T cells through the activation of purinergic P2X receptors. Sci. Signal. 4:ra12
199. Vergani A, Tezza S, D'Addio F, Fotino C, Liu K, et al. 2013. Long-term heart transplant survival by targeting the ionotropic purinergic receptor P2X7. Circulation 127:463-75
200. Vergani A, Fotino C, D'Addio F, Tezza S, Podetta M, et al. 2013. Effect of the purinergic inhibitor oxidized ATP in a model of islet allograft rejection. Diabetes 62:1665-75
201. Sharp AJ, Polak PE, Simonini V, Lin SX, Richardson JC, et al. 2008. P2x7 deficiency suppresses development of experimental autoimmune encephalomyelitis. J. Neuroinflamm. 5:33
202. Chen L, Brosnan CF. 2006. Exacerbation of experimental autoimmune encephalomyelitis in P2X7R-/- mice: evidence for loss of apoptotic activity in lymphocytes. J. Immunol. 176:3115-26
203. Taylor SR, Gonzalez-Begne M, Sojka DK, Richardson JC, Sheardown SA, et al. 2009. Lymphocytes from P2X7-deficient mice exhibit enhanced P2X7 responses. J. Leukoc. Biol. 85:978-86
204. Saul S, StaniszH, Backes CS, Schwarz EC,HothM. 2013. HowORAI and TRP channels interfere with each other: Interaction models and examples from the immune system and the skin. Eur. J. Pharmacol. 739:49-59
205. Wenning AS, Neblung K, Strauss B,Wolfs MJ, Sappok A, et al. 2011. TRP expression pattern and the functional importance of TRPC3 in primary human T-cells. Biochim. Biophys. Acta 1813:412-23
206. Wang J, Lu ZH, Gabius HJ, Rohowsky-Kochan C, Ledeen RW,Wu G. 2009. Cross-linking of GM1 ganglioside by galectin-1 mediates regulatory T cell activity involving TRPC5 channel activation: possible role in suppressing experimental autoimmune encephalomyelitis. J. Immunol. 182:4036-45
207. Suzuki Y, Kovacs CS, Takanaga H, Peng JB, Landowski CP, Hediger MA. 2008. Calcium channel TRPV6 is involved in murine maternal-fetal calcium transport. J. Bone Miner. Res. 23:1249-56
208. Guse AH, da Silva CP, Berg I, Skapenko AL,Weber K, et al. 1999. Regulation of calcium signalling in T lymphocytes by the second messenger cyclic ADP-ribose. Nature 398:70-73
209. Melzer N, Hicking G, Gobel K, Wiendl H. 2012. TRPM2 cation channels modulate T cell effector functions and contribute to autoimmune CNS inflammation. PLOS ONE 7:e47617
210. Weber KS, Hildner K, Murphy KM, Allen PM. 2010. Trpm4 differentially regulates Th1 and Th2 function by altering calcium signaling and NFAT localization. J. Immunol. 185:2836-46
211. Verheugen JA, Vijverberg HP, Oortgiesen M, Cahalan MD. 1995. Voltage-gated and Ca2+-activated K+ channels in intact human T lymphocytes. Noninvasivemeasurements ofmembrane currents, membrane potential, and intracellular calcium. J. Gen. Physiol. 105:765-94
212. Ghanshani S,Wulff H, MillerMJ,RohmH, NebenA, et al. 2000. Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences. J. Biol. Chem. 275:37137-49
213. Fanger CM, Neben AL, Cahalan MD. 2000. Differential Ca2+ influx, KCa channel activity, and Ca2+ clearance distinguish Th1 and Th2 lymphocytes. J. Immunol. 164:1153-60
214. FangerCM,Rauer H, NebenAL, MillerMJ, WulffH, et al. 2001. Calcium-activated potassium channels sustain calcium signaling in T lymphocytes. Selective blockers and manipulated channel expression levels. J. Biol. Chem. 276:12249-56
215. Ishida Y, Chused TM. 1993. Lack of voltage sensitive potassium channels and generation of membrane potential by sodium potassium ATPase in murine T lymphocytes. J. Immunol. 151:610-20
216. Koo GC, Blake JT, Talento A, Nguyen M, Lin S, et al. 1997. Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo. J. Immunol. 158:5120-28
217. Pereira LE, Villinger F,Wulff H, Sankaranarayanan A, Raman G, Ansari AA. 2007. Pharmacokinetics, toxicity, and functional studies of the selective Kv1.3 channel blocker 5-(4-phenoxybutoxy)psoralen in rhesus macaques. Exp. Biol. Med. 232:1338-54
218. Liu QH, Fleischmann BK, Hondowicz B, Maier CC, Turka LA, et al. 2002. Modulation of Kv channel expression and function by TCR and costimulatory signals during peripheral CD4+ lymphocyte differentiation. J. Exp. Med. 196:897-909
219. Grissmer S, Ghanshani S, Dethlefs B, McPherson JD, Wasmuth JJ, et al. 1992. The Shaw-related potassium channel gene, Kv3.1, on human chromosome 11, encodes the type l K+ channel in T cells. J. Biol. Chem. 267:20971-79
220. Beeton C, Chandy KG. 2005. Potassium channels,memoryTcells, and multiple sclerosis. Neuroscientist 11:550-62
221. Sallusto F, Geginat J, Lanzavecchia A. 2004. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22:745-63
222. WulffH, Calabresi PA, Allie R, Yun S, PenningtonM, et al. 2003. The voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS. J. Clin. Investig. 111:1703-13
223. Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, et al. 2006. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. PNAS 103:17414-19
224. Azam P, Sankaranarayanan A, Homerick D, Griffey S, Wulff H. 2007. Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis. J. Investig. Dermatol. 127:1419-29
225. Matheu MP, Beeton C, Garcia A, Chi V, Rangaraju S, et al. 2008. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity 29:602-14
226. Hu L, Gocke AR, Knapp E, Rosenzweig JM, Grishkan IV, et al. 2012. Functional blockade of the voltage-gated potassium channelKv1.3 mediates reversion ofTeffector to central memory lymphocytes through SMAD3/p21cip1 signaling. J. Biol. Chem. 287:1261-68
227. Chaigne-Delalande B, Li FY,O'ConnorGM, Lukacs MJ, Jiang P, et al. 2013. Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D. Science 341:186-91
228. Rezaei N, Hedayat M, Aghamohammadi A, Nichols KE. 2011. Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies. J. Allergy Clin. Immunol. 127:1329-41.e2
229. Desai B,Krapivinsky G, Navarro B, Krapivinsky L,Carter BC, et al. 2012. Cleavage of TRPM7 releases the kinase domain from the ion channel and regulates its participation in Fas-induced apoptosis. Dev. Cell 22(6):1149-62
230. Haase H, Rink L. 2009. Functional significance of zinc-related signaling pathways in immune cells. Annu. Rev. Nutr. 29:133-52
231. Hirano T, Murakami M, Fukada T, Nishida K, Yamasaki S, Suzuki T. 2008. Roles of zinc and zinc signaling in immunity: zinc as an intracellular signaling molecule. Adv. Immunol. 97:149-76
232. Honscheid A, Rink L, Haase H. 2009. T-lymphocytes: a target for stimulatory and inhibitory effects of zinc ions. Endocr. Metab. Immune Disord. Drug Targets 9:132-44
233. Kirchner H, Ruhl H. 1970. Stimulation of human peripheral lymphocytes by Zn2+ in vitro. Exp. Cell Res. 61:229-30
234. Fraker PJ, Jardieu P, Cook J. 1987. Zinc deficiency and immune function. Arch.Dermatol. 123:1699-701
235. Wellinghausen N, Martin M, Rink L. 1997. Zinc inhibits interleukin-1-dependent T cell stimulation. Eur. J. Immunol. 27:2529-35
236. Tanaka S, Akaishi E, Hosaka K, Okamura S, Kubohara Y. 2005. Zinc ions suppress mitogen-activated interleukin-2 production in Jurkat cells. Biochem. Biophys. Res. Commun. 335:162-67
237. Bjurstom H, Wang J, Ericsson I, BengtssonM, Liu Y, et al. 2008. GABA, a natural immunomodulator of T lymphocytes. J. Neuroimmunol. 205:44-50
238. Tian J, Chau C, HalesTG, KaufmanDL. 1999.GABAA receptorsmediate inhibition ofTcell responses. J. Neuroimmunol. 96:21-28
239. Tian J, Yong J, Dang H, Kaufman DL. 2011. Oral GABA treatment downregulates inflammatory responses in a mouse model of rheumatoid arthritis. Autoimmunity 44:465-70
240. Grinstein S, Clarke CA, Dupre A, Rothstein A. 1982. Volume-induced increase of anion permeability in human lymphocytes. J. Gen. Physiol. 80:801-23
241. Ben-Ari Y, Gaiarsa JL, Tyzio R, Khazipov R. 2007. GABA: a pioneer transmitter that excites immature neurons and generates primitive oscillations. Physiol. Rev. 87:1215-84
242. Spitzer NC. 2010. How GABA generates depolarization. J. Physiol. 588:757-58
243. Mueller C, Braag SA, Keeler A, Hodges C, Drumm M, Flotte TR. 2011. Lack of cystic fibrosis transmembrane conductance regulator in CD3+ lymphocytes leads to aberrant cytokine secretion and hyperinflammatory adaptive immune responses. Am. J. Respir. Cell Mol. Biol. 44:922-29
244. Mori Y, Wakamori M, Miyakawa T, Hermosura M, Hara Y, et al. 2002. Transient receptor potential 1 regulates capacitative Ca2+ entry and Ca2+ release from endoplasmic reticulum in B lymphocytes. J. Exp. Med. 195:673-81
245. Lievremont JP, Numaga T, Vazquez G, Lemonnier L, Hara Y, et al. 2005. The role of canonical transient receptor potential 7 in B-cell receptor-activated channels. J. Biol. Chem. 280:35346-51
246. LiuQH, Liu X,Wen Z, Hondowicz B, King L, et al. 2005. Distinct calcium channels regulate responses of primary B lymphocytes to B cell receptor engagement andmechanical stimuli. J. Immunol. 174:68-79
247. Bubien JK, Zhou LJ, Bell PD, Frizzell RA, Tedder TF. 1993. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J. Cell Biol. 121:1121-32
248. Anolik J, Looney RJ, Bottaro A, Sanz I, Young F. 2003. Down-regulation of CD20 on B cells upon CD40 activation. Eur. J. Immunol. 33:2398-409
249. Wulff H, Knaus HG, Pennington M, Chandy KG. 2004. K+ channel expression during B cell differentiation: implications for immunomodulation and autoimmunity. J. Immunol. 173:776-86
250. Moritoki Y, Lian ZX, Wulff H, Yang GX, Chuang YH, et al. 2007. AMA production in primary biliary cirrhosis is promoted by the TLR9 ligand CpG and suppressed by potassium channel blockers. Hepatology 45:314-22
251. Schmitz C, Perraud AL, Johnson CO, Inabe K, SmithMK, et al. 2003. Regulation of vertebrate cellular Mg2+ homeostasis by TRPM7. Cell 114:191-200
252. Hojyo S,Miyai T, FujishiroH,KawamuraM, Yasuda T, et al. 2014. Zinc transporter SLC39A10/ZIP10 controls humoral immunity by modulating B-cell receptor signal strength. PNAS 111:11786-91
253. Chen BC,Chou CF, LinWW.1998. Pyrimidinoceptor-mediated potentiation of inducible nitric-oxide synthase induction in J774 macrophages. Role of intracellular calcium. J. Biol. Chem. 273:29754-63
254. Watanabe N, Suzuki J, Kobayashi Y. 1996. Role of calcium in tumor necrosis factor-αproduction by activated macrophages. J. Biochem. 120:1190-95
255. Malik ZA, Denning GM, Kusner DJ. 2000. Inhibition of Ca2+ signaling by Mycobacterium tuberculosis is associated with reduced phagosome-lysosome fusion and increased survival within humanmacrophages. J. Exp. Med. 191:287-302
256. Vergne I, Chua J, Deretic V. 2003. Tuberculosis toxin blocking phagosome maturation inhibits a novel Ca2+/calmodulin-PI3K hVPS34 cascade. J. Exp. Med. 198:653-59
257. Zimmerli S, Majeed M, Gustavsson M, Stendahl O, Sanan DA, Ernst JD. 1996. Phagosome-lysosome fusion is a calcium-independent event in macrophages. J. Cell Biol. 132:49-61
258. Braun A, Gessner JE, Varga-Szabo D, Syed SN, Konrad S, et al. 2009. STIM1 is essential for Fcγ receptor activation and autoimmune inflammation. Blood 113:1097-104
259. Connolly SF, Kusner DJ. 2007. The regulation of dendritic cell function by calcium-signaling and its inhibition by microbial pathogens. Immunol. Res. 39:115-27
260. Hsu S, O'Connell PJ, Klyachko VA, Badminton MN, Thomson AW, et al. 2001. Fundamental Ca2+ signaling mechanisms in mouse dendritic cells: CRAC is the major Ca2+ entry pathway. J. Immunol. 166:6126-33
261. Matzner N, Zemtsova IM, Nguyen TX, Duszenko M, Shumilina E, Lang F. 2008. Ion channels modulating mouse dendritic cell functions. J. Immunol. 181:6803-9
262. Felix R, Crottes D, Delalande A, Fauconnier J, Lebranchu Y, et al. 2013. The Orai-1 and STIM-1 complex controls human dendritic cell maturation. PLOS ONE 8:e61595
263. Schaff UY, Dixit N, Procyk E, Yamayoshi I, Tse T, Simon SI. 2010. Orai1 regulates intracellular calcium, arrest, and shape polarization during neutrophil recruitment in shear flow. Blood 115:657-66
264. ZhangH,Clemens RA,Liu F,HuY, Baba Y, et al. 2014. STIM1 calcium sensor is required for activation of the phagocyte oxidase during inflammation and host defense. Blood 123:2238-49
265. Brechard S, Plancon S,MelchiorC,TschirhartEJ. 2009. STIM1 but not STIM2 is an essential regulator of Ca2+ influx-mediated NADPH oxidase activity in neutrophil-like HL-60 cells. Biochem. Pharmacol. 78:504-13
266. Steinckwich N, Schenten V, Melchior C, Brechard S, Tschirhart EJ. 2011. An essential role of STIM1, Orai1, and S100A8-A9 proteins for Ca2+ signaling and FcγR-mediated phagosomal oxidative activity. J. Immunol. 186:2182-91
267. Nunes P,CornutD, BochetV,HaslerU,Oh-hora M, et al. 2012. STIM1 juxtaposes ER to phagosomes, generating Ca2+ hotspots that boost phagocytosis. Curr. Biol. 22:1990-97
268. Gallin EK. 1981. Voltage clamp studies in macrophages from mouse spleen cultures. Science 214:458-60
269. Vicente R, Escalada A, ComaM, FusterG, Sanchez-Tillo E, et al. 2003. Differential voltage-dependent K+ channel responses during proliferation and activation in macrophages. J. Biol. Chem. 278:46307-20
270. Gallin EK. 1984. Calcium-and voltage-activated potassium channels in human macrophages. Biophys. J. 46:821-25
271. Hanley PJ, Musset B, Renigunta V, Limberg SH, Dalpke AH, et al. 2004. Extracellular ATP induces oscillations of intracellular Ca2+ and membrane potential and promotes transcription of IL-6 in macrophages. PNAS 101:9479-84
272. Chung I, Zelivyanskaya M, Gendelman HE. 2002. Mononuclear phagocyte biophysiology influences brain transendothelial and tissue migration: implication for HIV-1-associated dementia. J. Neuroimmunol. 122:40-54
273. Nelson DJ, Jow B, Jow F. 1992. Lipopolysaccharide induction of outward potassium current expression in humanmonocyte-derived macrophages: lack of correlationwith secretion. J. Membr. Biol. 125:207-18
274. Seydel U, Scheel O, Muller M, Brandenburg K, Blunck R. 2001. A K+ channel is involved in LPS signaling. J. Endotoxin Res. 7:243-47
275. DeCoursey TE, Kim SY, Silver MR, Quandt FN. 1996. Ion channel expression in PMA-differentiated human THP-1 macrophages. J. Membr. Biol. 152:141-57
276. Mackenzie AB, Chirakkal H, North RA. 2003. Kv1.3 potassium channels in human alveolar macrophages. Am. J. Physiol. Lung. Cell Mol. Physiol. 285:L862-68
277. LiuQH, Williams DA, McManus C, Baribaud F,Doms RW, et al. 2000. HIV-1 gp120 and chemokines activate ion channels in primarymacrophages through CCR5 and CXCR4 stimulation. PNAS 97:4832-37
278. Gao YD, Hanley PJ, Rinne S, Zuzarte M, Daut J. 2010. Calcium-activated K+ channel (KCa3.1) activity duringCa2+ store depletion and store-operatedCa2+ entry in human macrophages. Cell Calcium 48:19-27
279. Strobaek D, Brown DT, Jenkins DP, Chen YJ, ColemanN, et al. 2013. NS6180, a new KCa3.1 channel inhibitor prevents T-cell activation and inflammation in a rat model of inflammatory bowel disease. Br. J. Pharmacol. 168:432-44
280. Toyama K, Wulff H, Chandy KG, Azam P, Raman G, et al. 2008. The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans. J. Clin. Investig. 118:3025-37
281. Chen YJ, Lam J, Gregory CR, Schrepfer S, Wulff H. 2013. The Ca2+-activated K+ channel KCa3.1 as a potential new target for the prevention of allograft vasculopathy. PLOS ONE 8:e81006
282. FordyceCB, Jagasia R, Zhu X, Schlichter LC. 2005. Microglia Kv1.3 channels contribute to their ability to kill neurons. J. Neurosci. 25:7139-49
283. Maezawa I, CalafioreM,Wulff H, Jin LW. 2011. Does microglial dysfunction play a role in autism and Rett syndrome? Neuron Glia Biol. 7:85-97
284. Peng Y, Lu K, Li Z, Zhao Y, Wang Y, et al. 2014. Blockade of Kv1.3 channels ameliorates radiationinduced brain injury. Neuro Oncol. 16:528-39
285. Mauler F, Hinz V, Horvath E, Schuhmacher J, HofmannHA, et al. 2004. Selective intermediate-/smallconductance calcium-activated potassium channel (KCNN4) blockers are potent and effective therapeutics in experimental brain oedema and traumatic brain injury caused by acute subdural haematoma. Eur. J. Neurosci. 20:1761-68
286. Chen YJ, Raman G, Bodendiek S, O'Donnell ME, Wulff H. 2011. The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke. J. Cereb. Blood Flow Metab. 31:2363-74
287. Mullen KM, Rozycka M, Rus H, Hu L, Cudrici C, et al. 2006. Potassium channels Kv1.3 and Kv1.5 are expressed on blood-derived dendritic cells in the central nervous system. Ann. Neurol. 60:118-27
288. Kanneganti TD. 2010. Central roles of NLRs and inflammasomes in viral infection. Nat. Rev. Immunol. 10:688-98
289. Lamkanfi M, Dixit VM. 2012. Inflammasomes and their roles in health and disease. Annu. Rev. Cell Dev. Biol. 28:137-61
290. Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, et al. 2006. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440:228-32
291. Martinon F, Petrilli V, Mayor A,Tardivel A, Tschopp J. 2006. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237-41
292. Schroder K, Zhou R, Tschopp J. 2010. The NLRP3 inflammasome: a sensor for metabolic danger? Science 327:296-300
293. Tschopp J, Schroder K. 2010. NLRP3 inflammasome activation: the convergence ofmultiple signalling pathways on ROS production? Nat. Rev. Immunol. 10:210-15
294. Fernandes-Alnemri T, Yu JW, Datta P, Wu J, Alnemri ES. 2009. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 458:509-13
295. Bauernfeind F, Ablasser A, Bartok E, Kim S, Schmid-Burgk J, et al. 2011. Inflammasomes: current understanding and open questions. Cell. Mol. Life Sci. 68:765-83
296. Franchi L, Kamada N, Nakamura Y, Burberry A, Kuffa P, et al. 2012. NLRC4-driven production of IL-1βdiscriminates between pathogenic and commensal bacteria and promotes host intestinal defense. Nat. Immunol. 13:449-56
297. Munoz-Planillo R, Kuffa P,Martinez-Colon G, Smith BL, Rajendiran TM, Nunez G. 2013. K+ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 38:1142-53
298. Petrilli V, Papin S, Dostert C, Mayor A, Martinon F, Tschopp J. 2007. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ. 14:1583-89
299. Kahlenberg JM, Dubyak GR. 2004. Mechanisms of caspase-1 activation by P2X7 receptor-mediated K+ release. Am. J. Physiol. Cell Physiol. 286:C1100-8
300. Andrei C, Margiocco P, Poggi A, Lotti LV, Torrisi MR, Rubartelli A. 2004. Phospholipases C and A2 control lysosome-mediated IL-1βsecretion: implications for inflammatory processes. PNAS 101:9745-50
301. He Y, Franchi L, Nunez G. 2013. TLR agonists stimulate Nlrp3-dependent IL-1βproduction independently of the purinergic P2X7 receptor in dendritic cells and in vivo. J. Immunol. 190:334-39
302. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, et al. 2009. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors. Nat. Med. 15:1170-78
303. Wilhelm K,Ganesan J, Muller T,Durr C,Grimm M, et al. 2010. Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nat. Med. 16:1434-38
304. Azad AK, Sadee W, Schlesinger LS. 2012. Innate immune gene polymorphisms in tuberculosis. Infect. Immun. 80:3343-59
305. Coutinho-Silva R, Ojcius DM. 2012. Role of extracellular nucleotides in the immune response against intracellular bacteria and protozoan parasites. Microbes Infect. 14:1271-77
306. Kusner DJ, Adams J. 2000. ATP-induced killing of virulent Mycobacterium tuberculosis within human macrophages requires phospholipase D. J. Immunol. 164:379-88
307. Lammas DA, Stober C, Harvey CJ, Kendrick N, Panchalingam S, Kumararatne DS. 1997. ATPinduced killing ofmycobacteria by humanmacrophages is mediated by purinergic P2Z(P2X7) receptors. Immunity 7:433-44
308. Santos AA Jr, Rodrigues-Junior V, Zanin RF, Borges TJ, Bonorino C, et al. 2013. Implication of purinergic P2X7 receptor in M. tuberculosis infection and host interaction mechanisms: a mouse model study. Immunobiology 218:1104-12
309. Saunders BM, Fernando SL, Sluyter R, BrittonWJ, Wiley JS. 2003. A loss-of-function polymorphism in the human P2X7 receptor abolishes ATP-mediated killing ofmycobacteria. J. Immunol. 171:5442-46
310. Areeshi MY, Mandal RK, Panda AK, Bisht SC, Haque S. 2013. CD14-159 C>T gene polymorphism with increased risk of tuberculosis: evidence from a meta-analysis. PLOS ONE 8:e64747
311. Fernando SL, Saunders BM, Sluyter R, Skarratt KK, Goldberg H, et al. 2007. A polymorphism in the P2X7 gene increases susceptibility to extrapulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 175:360-66
312. Perraud AL, Takanishi CL, Shen B, Kang S, Smith MK, et al. 2005. Accumulation of free ADP-ribose from mitochondria mediates oxidative stress-induced gating of TRPM2 cation channels. J. Biol. Chem. 280:6138-48
313. KnowlesH, Li Y, Perraud AL. 2013. The TRPM2 ion channel, an oxidative stress and metabolic sensor regulating innate immunity and inflammation. Immunol. Res. 55:241-48
314. Knowles H, Heizer JW, Li Y, Chapman K, Ogden CA, et al. 2011. Transient receptor potential melastatin 2 (TRPM2) ion channel is required for innate immunity against Listeria monocytogenes. PNAS 108:11578-83
315. Yamamoto S, Shimizu S, Kiyonaka S, Takahashi N, Wajima T, et al. 2008. TRPM2-mediated Ca2+ influx induces chemokine production in monocytes that aggravates inflammatory neutrophil infiltration. Nat. Med. 14:738-47
316. Zhang Z, Zhang W, Jung DY, Ko HJ, Lee Y, et al. 2012. TRPM2 Ca2+ channel regulates energy balance and glucose metabolism. Am. J. Physiol. Endocrinol. Metab. 302:E807-16
317. Zhong Z, Zhai Y, Liang S, Mori Y, Han R, et al. 2013. TRPM2 links oxidative stress to NLRP3 inflammasome activation. Nat. Commun. 4:1611
318. Di A, Gao XP, Qian F, Kawamura T, Han J, et al. 2011. The redox-sensitive cation channel TRPM2 modulates phagocyte ROS production and inflammation. Nat. Immunol. 13:29-34
319. Serafini N, Dahdah A, Barbet G, Demion M, Attout T, et al. 2012. The TRPM4 channel controls monocyte and macrophage, but not neutrophil, function for survival in sepsis. J. Immunol. 189:3689-99
320. Barbet G, Demion M, Moura I, Serafini N, Léger T, et al. 2008. The calcium-activated nonselective cation channel TRPM4 is essential for the migration but not the maturation of dendritic cells. Nat. Immunol. 9:1148-56
321. Holmes B, Quie PG, Windhorst DB, Good RA. 1966. Fatal granulomatous disease of childhood. An inborn abnormality of phagocytic function. Lancet 1:1225-28
322. DeCoursey TE. 2010. Voltage-gated proton channels find their dream job managing the respiratory burst in phagocytes. Physiology 25:27-40
323. Femling JK, Cherny VV, Morgan D, Rada B, Davis AP, et al. 2006. The antibacterial activity of human neutrophils and eosinophils requires proton channels but not BK channels. J. Gen. Physiol. 127:659-72
324. Okamura Y, SasakiM. 2007. [Phagocytosis and membrane potential]. Seikagaku 79:454-58 (in Japanese)
325. Ramsey IS, Ruchti E, Kaczmarek JS, Clapham DE. 2009. Hv1 proton channels are required for highlevelNADPHoxidase-dependent superoxide production during the phagocyte respiratory burst. PNAS 106:7642-47
326. Shiloh MU, MacMicking JD, Nicholson S, Brause JE, Potter S, et al. 1999. Phenotype of mice and macrophages deficient in both phagocyte oxidase and inducible nitric oxide synthase. Immunity 10:29-38
327. Wu LJ,Wu G, Akhavan SharifMR, Baker A, Jia Y, et al. 2012. The voltage-gated proton channel Hv1 enhances brain damage from ischemic stroke. Nat. Neurosci. 15:565-73
328. Nowak JE, Harmon K, Caldwell CC, Wong HR. 2012. Prophylactic zinc supplementation reduces bacterial load and improves survival in a murine model of sepsis. Pediatr. Crit. Care Med. 13:e323-29
329. Brazao V, Caetano LC, Del Vecchio Filipin M, Paula Alonso Toldo M, Caetano LN, do Prado JC Jr. 2008. Zinc supplementation increases resistance to experimental infection by Trypanosoma cruzi. Vet. Parasitol. 154:32-37
330. Hasan R, Rink L,HaaseH. 2013. Zinc signals in neutrophil granulocytes are required for the formation of neutrophil extracellular traps. Innate Immun. 19:253-64
331. Haase H, Ober-Blobaum JL, Engelhardt G, Hebel S, Heit A, et al. 2008. Zinc signals are essential for lipopolysaccharide-induced signal transduction in monocytes. J. Immunol. 181:6491-502
332. RyuMS, Langkamp-HenkenB,Chang SM, ShankarMN,CousinsRJ. 2011. Genomic analysis, cytokine expression, and microRNA profiling reveal biomarkers of human dietary zinc depletion and homeostasis. PNAS 108:20970-75
333. Rink L, Haase H. 2007. Zinc homeostasis and immunity. Trends Immunol. 28:1-4
334. Liu MJ, Bao S, Galvez-Peralta M, Pyle CJ, Rudawsky AC, et al. 2013. ZIP8 regulates host defense through zinc-mediated inhibition of NF-κB. Cell Rep. 3:386-400
335. Sayadi A, Nguyen AT, Bard FA, Bard-Chapeau EA. 2013. Zip14 expression induced by lipopolysaccharides in macrophages attenuates inflammatory response. Inflamm. Res. 62:133-43
336. Kitamura H, Morikawa H, Kamon H, Iguchi M, Hojyo S, et al. 2006. Toll-like receptor-mediated regulation of zinc homeostasis influences dendritic cell function. Nat. Immunol. 7:971-77
337. Galli SJ, Tsai M. 2012. IgE and mast cells in allergic disease. Nat. Med. 18:693-704
338. Ashmole I, Duffy SM, Leyland ML, Morrison VS, Begg M, Bradding P. 2012. CRACM/Orai ion channel expression and function in human lung mast cells. J. Allergy Clin. Immunol. 129:1628-35 e2
339. Di Capite J, Nelson C, Bates G, Parekh AB. 2009. Targeting Ca2+ release-activated Ca2+ channel channels and leukotriene receptors provides a novel combination strategy for treating nasal polyposis. J. Allergy Clin. Immunol. 124:1014-21.e3
340. Wareham K, Vial C, Wykes RC, Bradding P, Seward EP. 2009. Functional evidence for the expression of P2X1, P2X4 and P2X7 receptors in human lung mast cells. Br. J. Pharmacol. 157:1215-24
341. Bulanova E, Bulfone-Paus S. 2010. P2 receptor-mediated signaling in mast cell biology. Purinergic Signal. 6:3-17
342. Kurashima Y, Amiya T, Nochi T, Fujisawa K, Haraguchi T, et al. 2012. Extracellular ATP mediates mast cell-dependent intestinal inflammation through P2X7 purinoceptors. Nat. Commun. 3:1034
343. Sudo N, Tanaka K, Koga Y, Okumura Y, Kubo C, Nomoto K. 1996. Extracellular ATP activates mast cells via a mechanism that is different from the activation induced by the cross-linking of Fc receptors. J. Immunol. 156:3970-79
344. Freichel M, Almering J, Tsvilovskyy V. 2012. The role of TRP proteins in mast cells. Front. Immunol. 3:150
345. Duffy SM, Lawley WJ, Conley EC, Bradding P. 2001. Resting and activation-dependent ion channels in human mast cells. J. Immunol. 167:4261-70
346. Duffy SM, Leyland ML, Conley EC, Bradding P. 2001. Voltage-dependent and calcium-activated ion channels in the human mast cell line HMC-1. J. Leukoc. Biol. 70:233-40
347. Shumilina E, Lam RS, Wolbing F, Matzner N, Zemtsova IM, et al. 2008. Blunted IgE-mediated activation of mast cells in mice lacking the Ca2+-activated K+ channel KCa3.1. J. Immunol. 180:8040-47
348. Girodet PO, Ozier A, Carvalho G, Ilina O, Ousova O, et al. 2013. Ca2+-activated K+ channel-3.1 blocker TRAM-34 attenuates airway remodeling and eosinophilia in a murine asthma model. Am. J. Respir. Cell Mol. Biol. 48:212-19
349. Van Der Velden J, Sum G, Barker D, Koumoundouros E, Barcham G, et al. 2013. KCa3.1 channelblockade attenuates airway pathophysiology in a sheep model of chronic asthma. PLOS ONE 8:e66886
350. Srivastava S, Cai X, Li Z, Sun Y, Skolnik EY. 2012. Phosphatidylinositol-3-kinase C2βand TRIM27 function to positively and negatively regulate IgE receptor activation of mast cells. Mol. Cell. Biol. 32:3132-39
351. Sobiesiak M, Shumilina E, Lam RS, Wolbing F, Matzner N, et al. 2009. Impaired mast cell activation in gene-targeted mice lacking the serum-and glucocorticoid-inducible kinase SGK1. J. Immunol. 183:4395-402
352. Wolbing F, Sobiesiak M, Shumilina E, Kaesler S, Lam RS, et al. 2009. Impaired anaphylaxis and mast cell degranulation in mice lacking serum-and glucocorticoid-inducible kinase. J. Investig. Dermatol. 129:S8
353. Vennekens R, Olausson J, Meissner M, BlochW, Mathar I, et al. 2007. Increased IgE-dependent mast cell activation and anaphylactic responses in mice lacking the calcium-activated nonselective cation channel TRPM4. Nat. Immunol. 8:312-20
354. Yamasaki S, Sakata-Sogawa K, Hasegawa A, Suzuki T, Kabu K, et al. 2007. Zinc is a novel intracellular second messenger. J. Cell Biol. 177:637-45
355. Kabu K, Yamasaki S, Kamimura D, Ito Y, Hasegawa A, et al. 2006. Zinc is required for Fc epsilon RI-mediated mast cell activation. J. Immunol. 177:1296-305
356. Di Sabatino A, Rovedatti L, Kaur R, Spencer JP, Brown JT, et al. 2009. Targeting gut T cell Ca2+ release-activated Ca2+ channels inhibits T cell cytokine production and T-box transcription factor T-bet in inflammatory bowel disease. J. Immunol. 183:3454-62
357. Derler I, Schindl R, Fritsch R, Heftberger P, Riedl MC, et al. 2013. The action of selective CRAC channel blockers is affected by the Orai pore geometry. Cell Calcium 53:139-51
358. Chen G, Panicker S, Lau KY, Apparsundaram S, Patel VA, et al. 2013. Characterization of a novel CRAC inhibitor that potently blocks human T cell activation and effector functions. Mol. Immunol. 54:355-67
359. Grundy S, Kaur M, Plumb J, Reynolds S,Hall S, et al. 2014. CRAC channel inhibition produces greater anti-inflammatory effects than glucocorticoids in CD8 cells from COPD patients. Clin. Sci. 126:223-32
360. Yoshino T, Ishikawa J, Ohga K, Morokata T, Takezawa R, et al. 2007. YM-58483, a selective CRAC channel inhibitor, prevents antigen-induced airway eosinophilia and late phase asthmatic responses via Th2 cytokine inhibition in animal models. Eur. J. Pharmacol. 560:225-33
361. Cox JH, Hussell S, Sondergaard H, Roepstorff K, Bui JV, et al. 2013. Antibody-mediated targeting of the orai1 calcium channel inhibits T cell function. PLOS ONE 8:e82944
362. Lin FF, Elliott R, Colombero A, Gaida K, Kelley L, et al. 2013. Generation and characterization of fully human monoclonal antibodies against human Orai1 for autoimmune disease. J. Pharmacol. Exp. Ther. 345:225-38
363. Gaida K, Salimi-Moosavi H, Subramanian R, Almon V, Knize A, et al. 2014. Inhibition of CRAC with a human anti-ORAI1 monoclonal antibody inhibits T-cell-derived cytokine production but fails to inhibit a T-cell-dependent antibody response in the cynomolgus monkey. J. Immunotoxicol. 3:1-10
364. Cheng KT, Alevizos I, Liu X, Swaim WD, Yin H, et al. 2012. STIM1 and STIM2 protein deficiency in T lymphocytes underlies development of the exocrine gland autoimmune disease, Sjogren's syndrome. PNAS 109:14544-49
365. Chandy KG, DeCoursey TE, Cahalan MD, McLaughlin C, Gupta S. 1984. Voltage-gated potassium channels are required for human T lymphocyte activation. J. Exp. Med. 160:369-85
366. Wulff H, Beeton C, Chandy KG. 2003. Potassium channels as therapeutic targets for autoimmune disorders. Curr. Opin. Drug Discov. Devel. 6:640-47
367. Beeton C, Pennington MW, Wulff H, Singh S, Nugent D, et al. 2005. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol. Pharmacol. 67:1369-81
368. Rus H, Pardo CA, Hu L, Darrah E, Cudrici C, et al. 2005. The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. PNAS 102:11094-99
369. Beeton C, Barbaria J, Giraud P, Devaux J, Benoliel AM, et al. 2001. Selective blocking of voltagegatedK + channels improves experimental autoimmune encephalomyelitis and inhibitsTcell activation. J. Immunol. 166:936-44
370. Beeton C, Wulff H, Barbaria J, Clot-Faybesse O, Pennington M, et al. 2001. Selective blockade of T lymphocyte K+ channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. PNAS 98:13942-47
371. Tarcha EJ, Chi V, Munoz-Elias EJ, Bailey D, Londono LM, et al. 2012. Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppressesTcell mediators of autoimmune disease. J. Pharmacol. Exp. Ther. 342:642-53
372. Hyodo T, Oda T, Kikuchi Y, Higashi K, Kushiyama T, et al. 2010. Voltage-gated potassium channel Kv1.3 blocker as a potential treatment for rat anti-glomerular basement membrane glomerulonephritis. Am. J. Physiol. Renal Physiol. 299:F1258-69
373. Gilhar A, Bergman R, Assay B, Ullmann Y, Etzioni A. 2011. The beneficial effect of blocking Kv1.3 in the psoriasiform SCID mouse model. J. Investig. Dermatol. 131:118-24
374. Gilhar A, Keren A, Shemer A, Ullmann Y, Paus R. 2013. Blocking potassium channels (Kv1.3): a new treatment option for alopecia areata? J. Investig. Dermatol. 133:2088-91
375. Kundu-Raychaudhuri S, Chen YJ, Wulff H, Raychaudhuri SP. 2014. Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis-Xenograft model. J. Autoimmun. 55:63-72
376. Koshy S, Huq R, TannerMR, Atik MA, Porter PC, et al. 2014. Blocking KV1.3 channels inhibits Th2 lymphocyte function and treats a rat model of asthma. J. Biol. Chem. 289:12623-32
377. Edwards W, Fung-Leung WP, Huang C, Chi E, Wu N, et al. 2014. Targeting the ion channel Kv1.3 with scorpion venom peptides engineered for potency, selectivity, and half-life. J. Biol.Chem. 289:22704-14
378. Cruse G, Duffy SM, Brightling CE, Bradding P. 2006. Functional KCa3.1 K+ channels are required for human lung mast cell migration. Thorax 61:880-85
379. Ataga KI, Stocker J. 2009. Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia. Expert Opin. Investig. Drugs 18:231-39
380. Bartlett R, Stokes L, Sluyter R. 2014. The P2X7 receptor channel: recent developments and the use of P2X7 antagonists in models of disease. Pharmacol. Rev. 66:638-75
381. Arulkumaran N, Unwin RJ, Tam FW. 2011. A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases. Expert Opin. Investig. Drugs 20:897-915
382. Taylor SR, Turner CM, Elliott JI, McDaid J, Hewitt R, et al. 2009. P2X7 deficiency attenuates renal injury in experimental glomerulonephritis. J. Am. Soc. Nephrol. 20:1275-81
383. Keystone EC,Wang MM, LaytonM, Hollis S, McInnes IB. 2012. Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann. Rheum. Dis. 71:1630-35
384. Stock TC, Bloom BJ, Wei N, Ishaq S, Park W, et al. 2012. Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J. Rheumatol. 39:720-27
385. Hou X, Pedi L, Diver MM, Long SB. 2012. Crystal structure of the calcium release-activated calcium channel Orai. Science 338:1308-13